This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

NovoSeven® is indicated for the treatment of bleeding  episodes and for the prevention of bleeding in surgery or  invasive procedures in patients with congenital haemophilia  with inhibitors to coagulation factors VIII or IX, congenital  haemophilia expected to have a high anamnestic response to factor VIII or factor IX, acquired haemophilia, congenital FVII  deficiency, and Glanzmann’s thrombasthenia with past or  present refractoriness to platelet transfusions or where  platelets are not readily available.1

NovoSeven® is indicated for the treatment of severe  postpartum haemorrhage when uterotonics are insufficient  to achieve haemostasis.1,2

1.

NovoSeven® Summary of Product Characteristics.

2.

Committee for Medicinal Products for Human Use (CHMP), “CHMP extension of indication variation assessment report (NovoSeven®), `EPAR’”; 22 April 2022. Procedure No. EMEA/H/C/000074/II/0116.

3.

Poon MC. Vasc Health Risk Manag 2007;3(5): 655–664

4.

Hers I et al. Platelets 2008;19(8):571–581.

5.

Kjalke M et al. Br J Haematol 2001;114(1):114–120.

6.

Lisman T et al. Blood 2004;103(5):1720–1727.

7.

Weeterings C et al. Blood 2008;112(8):3227–3233.

8.

Di Minno G et al. Haematologica 2015;100(8):1031–7.

9.

Poon MC et al. Haematologica 2015;100(8):1038–44.

10.

Pollard D et al. J Haem Pract 2017;4(1):1–5.

11.

Neufeld EJ et al. Blood Rev 2015;29(Suppl 1):S34–S41.

12.

Neufeld EJ et al. Haemophilia 2018;24(4):e275–e277.

13.

Croom KF, McCormack PL. Biodrugs 2008;22(2):121–36.

14.

Hedner U. Blood Rev 2015;29(Suppl 1):S4–S8.

15.

Rexen P et al. TH Open 2019;3:e45–e49.

16.

FEIBA® Summary of Product Characteristics.

17.

Santagostino E et al. Thromb Haemost 2006;4(2):367–371.

18.

Neufeld EJ et al. Pediatr Blood Cancer 2013;60(7):1178–1183.

19.

Pruthi RK et al. Thromb Haemost 2007;98(4):726–732.

20.

Shapiro AD et al. Thromb Haemost 1998;80(5):773–778.

21.

Parameswaran R et al. Haemophilia 2005;11(2):100–106.

22.

Hay CR et al. Thromb Haemost 1997;7(8):1463–1467.

23.

Amano K et al. Haemophilia 2016;23(1):50–58.

24.

Baudo F et al. Blood 2012;120(1):39–46.

25.

Borel-Derlon A et al. Haemophilia 2016;22 Suppl 4:3–138. Poster PO-W-4.

26.

Sumner MJ et al. Haemophilia 2007;13(5):451–461.

27.

Lentz SR et al. J Blood Med 2014;5:1–3.

28.

Sun B et al. Br J Haematol 2019. doi: 10.1111/bjh.16128. [Epub ahead of print].

29.

Pardos-Gea J et al. Haemophilia 2018;24(3):e163–e166.

30.

Tiede A, Worster A. Ann Hematol 2018;97(10):1889–1901.

31.

Abshire T, Kenet G. Haemophilia 2008;14(5):898–902.

32.

Hemlibra® Summary of Product Characteristics.